Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02169271 · ClinicalTrials.gov registry record · Phase 2

Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
109
Enrollment target

NCT02169271: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT02169271 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 109 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02169271, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
109 participants
Enrollment target

Study Summary

This randomized phase II trial studies acetylsalicylic acid compared to placebo in treating high-risk patients with subsolid lung nodules. A nodule is a growth or lump that may be malignant (cancer) or benign (not cancer). Chemoprevention is the use of drugs to keep cancer from forming or coming back. The use of acetylsalicylic acid may keep cancer from forming in patients with subsolid lung nodules.

Primary Outcome

Difference (12 month-baseline) in the sum of longest diameters of baseline target nodules.

Interventions

  • OTHER Placebo
  • OTHER Laboratory Biomarker Analysis
  • DRUG Aspirin

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2014-11-21
Est. Completion 2020-02-14
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT02169271 record still lists

NCT02169271 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02169271 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02169271 about?

NCT02169271 is a clinical study titled "Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules". This randomized phase II trial studies acetylsalicylic acid compared to placebo in treating high-risk patients with subsolid lung nodules. A nodule is a growth or lump that may be malignant (cancer) or benign (not cancer). Chemoprevention is the use of drugs to keep cancer from forming or coming bac...

What is the current status of trial NCT02169271?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2014-11-21. Estimated completion is 2020-02-14.

What interventions are being tested in trial NCT02169271?

The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Aspirin (DRUG).

Who is sponsoring clinical trial NCT02169271?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02169271's enrollment target sits among peer trials

109 640th of 2000 higher than 1,361 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02421380 · 109 participants · NA

    Characterization of Hyperpolarized Pyruvate MRI Reproducibility

  • NCT04526600 · 109 participants · NA

    Fidgeting and Attentional and Emotional Regulation in ADHD

  • NCT04835584 · 109 participants · Phase 1

    KRT-232 and TKI Study in Chronic Myeloid Leukemia

  • NCT06626516 · 109 participants · Phase 1

    Tebentafusp-tebn With LDT in Metastatic UM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02169271, the US trial registry maintained by the National Library of Medicine. NCT02169271 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.